REVISED

Medicaid Preferred Drug List (PDL) Program: Pharmacy and Therapeutics Committee Meeting

Wednesday, July 30, 2003 10:00 a.m. to 1:00 p.m., DMAS Board Room

AGENDA

• Welcome and Introductions Patrick W. Finnerty,
Director

 Acceptance of Minutes from June 18th Meeting
 Randy Axelrod, M.D. Chairman, P&T Committee

• Comments from the Chairperson Randy Axelrod, M.D.

Introduction and Overview by First Health
 Services Corporation
 Annette Paul,
 First Health Services Corporation

• Drug Class Discussions:

Randy Axelrod, M.D and
P&T Committee

Proton Pump Inhibitors (PPI)
Histamine Type-2 Receptor Antagonists (H2RA)
Antihistamines
Nasal Steroids

 Presentations on Drug Specific Clinical Information
 Randy Axelrod, M.D. and Interested Parties

• Next Meeting Randy Axelrod, M.D.

Written information/presentations: The P&T Committee will accept written comments for consideration. Please send information to pdlinput@dmas.state.va.us by COB Monday July 28, 2003.

Oral presentations: The P&T Committee in conjunction with the Department will be allocating a limited number of slots for interested parties to present clinical information on the specific drug classes that are listed on the Agenda. Each speaker will be allocated to a 3 - 5 minutes time slot. The actual speakers and number of speakers will be decided by the Chairperson based on relevancy of the information and time limitations.

If you are interested in providing specific clinical drug information, please submit your written comments or an outline of discussion points and indicate your request to speak at the meeting. Please send information to pdlinput@dmas.state.va.us by COB Monday July 28, 2003.